05B4 Waldman, Scott - Thomas Jefferson University - Thomas Jefferson University

Scott A.. Waldman, MD, PhD

Contact Dr. Waldman

132 South 10th Street
Suite 1170
Philadelphia, PA 19107

(215) 955-6086
(215) fax

Most Recent Peer-reviewed Publications

  1. Big data transforms discoveryutilization therapeutics continuum
  2. Obesity-induced colorectal cancer is driven by caloric silencing of the guanylin-GUCY2C paracrine signaling axis
  3. Bioinnovation Enterprise: An Engine Driving Breakthrough Therapies
  4. Guanylyl cyclase C as a biomarker
  5. CD19-targeted nanodelivery of doxorubicin enhances therapeutic efficacy in B-cell acute lymphoblastic leukemia
  6. Companion diagnostics at the intersection of personalized medicine and healthcare delivery
  7. Clinical pharmacology & therapeutics: The next five years
  8. A novel CDX2 isoform regulates alternative splicing
  9. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C
  10. Managing the innovation supply chain to maximize personalized medicine
  11. Antiobesity pharmacotherapy: New drugs and emerging targets
  12. GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer
  13. Policies to aid the adoption of personalized medicine
  14. Selective antigen-specific CD4+ T-cell, but not CD8+ T- or B-cell, tolerance corrupts cancer immunotherapy
  15. Molecular insights provide the critical path to disease mitigation
  16. The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer
  17. Erratum: Cardiopoietic stem cell therapy in heart failure: The C-CURE (Cardiopoietic stem Cell therapy in heart failURE) Multicenter randomized trial with lineage-specified biologics (Journal of the American College of Cardiology (2013) 61 (2329-2338))
  18. Genetics and genomics for the prevention and treatment of cardiovascular disease: Update a scientific statement from the american heart association
  19. Reply: The C-CURE randomized clinical trial (Cardiopoietic stem Cell therapy in heart failURE)
  20. Intestinal GUCY2C prevents TGF-β secretion coordinating desmoplasia and hyperproliferation in colorectal cancer